Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03225287
Registration number
NCT03225287
Ethics application status
Date submitted
17/07/2017
Date registered
21/07/2017
Date last updated
28/09/2023
Titles & IDs
Public title
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
Query!
Scientific title
A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
Query!
Secondary ID [1]
0
0
2016-003523-34
Query!
Secondary ID [2]
0
0
RA101495-01.202
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Paroxysmal Nocturnal Hemoglobinuria (PNH)
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Zilucoplan (RA101495)
Experimental: Zilucoplan (RA101495) - Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
Treatment: Drugs: Zilucoplan (RA101495)
Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Query!
Assessment method [1]
0
0
TEAEs were defined as an AE that occurs after a participant's initial treatment zilucoplan start for this study (RA101495-01.202) that was not present at the time of treatment start, or an AE that increases in severity after treatment start in this study, if the event was present at the time of treatment start.
Query!
Timepoint [1]
0
0
From Day 1 until the Final Study Visit (up to Month 49)
Query!
Primary outcome [2]
0
0
Percentage of Participants With Serious TEAEs
Query!
Assessment method [2]
0
0
Serious Adverse event (SAE) was defined as any untoward medical occurrence that:• results in death, • is life-threatening threatening (note that this refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe), • requires hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, and • results in a congenital anomaly/birth defect.
Query!
Timepoint [2]
0
0
From Day 1 until the Final Study Visit (up to Month 49)
Query!
Secondary outcome [1]
0
0
Number of Participants With Anti-drug Antibodies (ADA)
Query!
Assessment method [1]
0
0
Blood samples collection were planned to analyze for the presence/absence of ADAs to zilucoplan for immunogenicity assessments.
Query!
Timepoint [1]
0
0
At Day 1, Month 1, 2, 3, 6, 9, and 12
Query!
Secondary outcome [2]
0
0
Change From Baseline in Serum Lactate Dehydrogenase (LDH) Levels at Each Time Point
Query!
Assessment method [2]
0
0
Serum LDH levels were measure of intravascular hemolysis. As high level of LDH in the blood was indicative of hemolysis in participants with PNH.
Query!
Timepoint [2]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Query!
Secondary outcome [3]
0
0
Change From Baseline in Total Bilirubin Values at Each Time Point
Query!
Assessment method [3]
0
0
Total Bilirubin was monitored for signs and symptoms of hepatic or biliary dysfunction.
Query!
Timepoint [3]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Query!
Secondary outcome [4]
0
0
Change From Baseline in Total Hemoglobin Values at Each Time Point
Query!
Assessment method [4]
0
0
Total Hemoglobin Values were analyzed for hematology assessments.
Query!
Timepoint [4]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Query!
Secondary outcome [5]
0
0
Change From Baseline in Free Hemoglobin Values at Each Time Point
Query!
Assessment method [5]
0
0
Free Hemoglobin Values were analyzed for hematology assessments.
Query!
Timepoint [5]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Query!
Secondary outcome [6]
0
0
Change From Baseline in Haptoglobin Values at Each Time Point
Query!
Assessment method [6]
0
0
Haptoglobin values were analyzed for hematology assessments.
Query!
Timepoint [6]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Query!
Secondary outcome [7]
0
0
Change From Baseline in Reticulocytes at Each Time Point
Query!
Assessment method [7]
0
0
Reticulocytes values were analyzed for hematology assessments.
Query!
Timepoint [7]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and Final Study Visit (Month 49)
Query!
Secondary outcome [8]
0
0
Change From Baseline in Hemoglobinuria Values at Each Time Point
Query!
Assessment method [8]
0
0
Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10 where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.
Query!
Timepoint [8]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and Final Study Visit (Month 49)
Query!
Secondary outcome [9]
0
0
Plasma Concentrations of RA101495 and Its Major Metabolite(s)
Query!
Assessment method [9]
0
0
Blood samples of RA101495 (zilucoplan) and its metabolites (RA102758 and RA103488) were collected for Plasma concentration analysis.
Query!
Timepoint [9]
0
0
Predose: At Day 1 (Screening), Month 1, 2, 3, 6, 9, 12, and Final Study Visit (Month 49)
Query!
Secondary outcome [10]
0
0
Maximum Plasma Concentration (Cmax) of RA101495
Query!
Assessment method [10]
0
0
Cmax is the maximum plasma concentration.
Query!
Timepoint [10]
0
0
At Day 1, Month 1, 2, 3, 6, 9, and 12
Query!
Secondary outcome [11]
0
0
Time Corresponding to Cmax (Tmax) of RA101495
Query!
Assessment method [11]
0
0
tmax is the time to corresponding Cmax.
Query!
Timepoint [11]
0
0
At Day 1, Month 1, 2, 3, 6, 9, and 12
Query!
Secondary outcome [12]
0
0
Area Under the Drug Concentration-time Curve (AUC0-t) of RA101495
Query!
Assessment method [12]
0
0
AUC0-t is area under the drug concentration-time curves.
Query!
Timepoint [12]
0
0
At Day 1, Month 1, 2, 3, 6, 9, and 12
Query!
Secondary outcome [13]
0
0
Total Complement (CH50) Levels
Query!
Assessment method [13]
0
0
Blood samples collection were planned to assess complement (CH50) levels. The planned analysis of CH50 was not performed because the CH50 assay was not able to be validated due to lack of reproducibility of the manufacturer's kits.
Query!
Timepoint [13]
0
0
At Day 1, Month 1, 2, 3, 6, 9, and 12
Query!
Secondary outcome [14]
0
0
Change From Baseline in Sheep Red Blood Cell (sRBC) Values at Each Time Point
Query!
Assessment method [14]
0
0
Blood samples were collected for measurement of sRBC lysis for the Classical Complement Pathways.
Query!
Timepoint [14]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12 and Final Study Visit (Month 49)
Query!
Secondary outcome [15]
0
0
Change From Baseline in Wieslab Enzyme-linked Immunosorbent Assay (ELISA) Values for Alternative Complement Pathway at Each Time Point
Query!
Assessment method [15]
0
0
Blood samples were collected for measurement of membrane attack complex (MAC) by Wieslab ELISA for alternative complement pathway.
Query!
Timepoint [15]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12 and Final Study Visit (Month 49)
Query!
Secondary outcome [16]
0
0
Change From Baseline in Complement Component 5 (C5) Values at Each Time Point
Query!
Assessment method [16]
0
0
Blood samples were collected for measurement of Complement component 5 (C5) levels.
Query!
Timepoint [16]
0
0
Baseline, Month 1, 2, 3, 6, 9, 12 and Final Study Visit (Month 49)
Query!
Eligibility
Key inclusion criteria
- Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH
study
- Evidence of ongoing clinical benefit in the opinion of the Investigator
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- History of meningococcal disease
- Current systemic infection or suspicion of active bacterial infection
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/07/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/10/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
19
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigative Site 3 - Gosford
Query!
Recruitment hospital [2]
0
0
Investigative Site 5 - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Gosford
Query!
Recruitment postcode(s) [2]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Texas
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Toronto
Query!
Country [4]
0
0
Finland
Query!
State/province [4]
0
0
Helsinki
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Ulm
Query!
Country [6]
0
0
Hungary
Query!
State/province [6]
0
0
Budapest
Query!
Country [7]
0
0
New Zealand
Query!
State/province [7]
0
0
Christchurch
Query!
Country [8]
0
0
New Zealand
Query!
State/province [8]
0
0
Hamilton
Query!
Country [9]
0
0
United Kingdom
Query!
State/province [9]
0
0
Leeds
Query!
Country [10]
0
0
United Kingdom
Query!
State/province [10]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Ra Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients
with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical
study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03225287
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Dr. Anita Hill
Query!
Address
0
0
St James' Institute of Oncology
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03225287
Download to PDF